Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis

Internal Medicine Journal

Volumn 39, Issue 5, 2009, Pages 296-303

  Lester, S E ^a   Proudman, S M ^b   Lee, A T Y ^b   Hall, C A ^b   McWilliams, L ^b   James, M J ^b   Cleland, L G ^a,b  

^a Hanson Research Institute   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Disease activity; Disease modifying anti inflammatory drug; Leucopenia; Rheumatoid arthritis

Indexed keywords

AUROTHIOMALATE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; ICOSAPENTAENOIC ACID; LEFLUNOMIDE; METHOTREXATE; OMEGA 3 FATTY ACID; SALAZOSULFAPYRIDINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SURVEILLANCE; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL COUNT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTE COUNT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD CELL COUNT; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650924512     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01737.x     Document Type: Article

References (40)

1. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 2005 44 : 61 6.
2. Marabani M, Madhok R, Capell HA, Hunter JA. Leucopenia during sulphasalazine treatment for rheumatoid arthritis. Ann Rheum Dis 1989 48 : 505 7.
3. Schneemann M. Antiprotozoal drugs. In : Dukes MNG, Aronson JK, eds. Myler's Side Effects of Drugs. New York : Elsevier 2000 947 58.
4. eMIMS. 2006. http://www.mims.com.au
5. Yan A, Davis P. Gold induced marrow suppression: a review of 10 cases. J Rheumatol 1990 17 : 47 51. (Pubitemid 20070567)
6. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003 62 : 4 9. (Pubitemid 36005787)
7. Hamilton JA. Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. Lancet 1993 342 : 536 9.
8. Hamilton JA, Williams N. In vitro inhibition of myelopoiesis by gold salts and D-penicillamine. J Rheumatol 1985 12 : 892 6.
9. Hamilton JA, Williams N. Effects of auranofin and other antirheumatic drugs on human myelopoiesis in vitro. J Rheumatol 1987 14 : 216 20.
10. Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J 2000 76 : 787 9.
11. Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007, 37 : 99 111. (Pubitemid 350198583)
12. Stamp LK, James MJ, Cleland LG. Diet and rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 2005 35 : 77 94. (Pubitemid 41356585)
13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 38 : 44 8.
14. Farr M, Tunn EJ, Symmons DP, Scott DG, Bacon PA. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 1989 28 : 134 8.
15. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989 32 : 1592 6.
16. Brown AJ, Roberts DC. Fish and fish oil intake: effect on haematological variables related to cardiovascular disease. Thromb Res 1991 64 : 169 78.
17. Akahoshi T, Namai R, Sekiyama N, Tanaka S, Hosaka S, Kondo H. Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J Leukoc Biol 1997 62 : 817 26.
18. Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 1999 128 : 1361 9.
19. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The induction of apoptosis by methotrexate in activated lymphocytes as indicated by fluorescence hyperpolarization: a possible model for predicting methotrexate therapy for rheumatoid arthritis patients. Cell Struct Funct 2003 28 : 113 22.
20. Papaconstantinou HT, Xie C, Zhang W, Ansari NH, Hellmich MR, Townsend CM Jr. et al. The role of caspases in methotrexate-induced gastrointestinal toxicity. Surgery 2001 130 : 859 65.
21. Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, Han SH. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001 166 : 6914 24.
22. Avula CP, Zaman AK, Lawrence R, Fernandes G. Induction of apoptosis and apoptotic mediators in Balb/C splenic lymphocytes by dietary n-3 and n-6 fatty acids. Lipids 1999 34 : 921 7.
23. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000 165 : 5962 9.
24. Caughey GE, Pouliot M, Cleland LG, James MJ. Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes. J Immunol 1997 158 : 351 8.
25. Caughey GE, Cleland LG, Gamble JR, James MJ. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 2001 276 : 37839 45.
26. Ostrovsky L, King AJ, Bond S, Mitchell D, Lorant DE, Zimmerman GA et al. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood 1998 91 : 3028 36.
27. Sprent J, Tough DF. Lymphocyte life-span and memory. Science 1994 265 : 1395 400.
28. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 2002 46 : 2553 63.
29. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004 50 : 2433 40.
30. Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995 86 : 3181 8.
31. Farsky SP, Sannomiya P, Garcia-Leme J. Secreted glucocorticoids regulate leukocyte-endothelial interactions in inflammation. A direct vital microscopic study. J Leukoc Biol 1995 57 : 379 86.
32. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993 119 : 1198 208.
33. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004 141 : 764 70.
34. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005 52 : 722 32.
35. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005 52 : 3360 70.
36. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007 1 CD 006356.
37. Andres E, Maloisel F. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med 2001 161 : 2619.
38. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002 46 : 283 5.
39. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004 364 : 263 9.
40. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005 52 : 3381 90.